TAZ and YAP dysregulation in sarcomas
Iowa Research Online (The University of Iowa) · 01.01.2024
DOI: 10.25820/etd.006506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iowa Research Online (The University of Iowa), erschienen am 01.01.2024. Verfasst von Keith C. Garcia.
Abstract (Originalsprache)
Sarcomas are comprised of a diverse group of cancers with over 50 histological types, which are difficult to treat. In addition to lack of medical therapies, the mechanisms that drive sarcomagenesis remain to be fully understood. Current treatment modalities for localized disease, which has a survival rate of approximately 60%, often involves surgical resection. Depending on the size and location of the tumor, radiation may be employed prior to surgical removal. The 5-year survival rate for patients that develop metastatic disease is around 15-20%. Treatment for metastatic sarcoma is limited and often involves toxic chemotherapeutic agents, such as doxorubicin, a topoisomerase inhibitor, which can lead to severe cardiotoxic effects. Therefore, there is a critical need to identify actionable targets for therapeutic benefit in the treatment of sarcomas.We currently know that the Hippo tumor suppressor pathway plays a critical role in a majority of sarcomas. Downstream effectors of the Hippo pathway are two transcriptional co-activators, TAZ (transcriptional coactivator with PDZ-binding motif) and its paralogue YAP (yes associated protein). In sarcomas as well as other cancer types including breast, colorectal, ovarian, liver, pancreas, and thyroid cancer, this pathway is disrupted leading to a hyperactive TAZ and YAP oncogenic transcriptional activity. TAZ and YAP are activated in >50% of sarcomas and many of these sarcomas exhibit loss of expression of the Hippo tumor suppressor kinases, MST1/2 or LATS 1/2. Importantly, activating point mutations in TAZ and YAP are rare and alterations of these proteins are often involved in gene rearrangements resulting in oncogenic fusion proteins.
Schlagwörter
Zitieren
APA
Garcia, K. C. (2024). TAZ and YAP dysregulation in sarcomas. Iowa Research Online (The University of Iowa). https://doi.org/10.25820/etd.006506
Vancouver
Garcia KC. TAZ and YAP dysregulation in sarcomas. Iowa Research Online (The University of Iowa). 2024. doi:10.25820/etd.006506
BibTeX
@article{Garcia2024,
author = {Garcia, Keith C.},
title = {TAZ and YAP dysregulation in sarcomas},
journal = {Iowa Research Online (The University of Iowa)},
year = {2024},
doi = {10.25820/etd.006506}
}
EUVIMED